CPT 81434: Retinal Disorders Genomic Sequence Analysis Panel
Commercial payers pay $559 on average nationally for this procedure.
CPT code 81434 describes a laboratory-performed genomic sequence analysis panel that evaluates a patient specimen for genetic variants across a set of at least 15 genes associated with retinal disorders, representing clinical molecular diagnostic testing typically performed as a multigene next-generation sequencing panel; the service type is genetic testing / genomic sequence analysis and the typical site of service is a clinical diagnostic laboratory or reference molecular genetics laboratory where specimens are processed and sequenced.
Customize your policy alerts
Sign up for cpt 81434 policy alerts
Get alerted when payer policies referencing 81434 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial rates for CPT 81434 center around BUCA’s mean of $558.80 as a proxy for average commercial reimbursement; several large national payers trade around that level but with meaningful spread. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $713.40, and Cigna’s IQR is $511.20, both notably wider than BUCA’s IQR of $344.10. Aetna and UnitedHealth Group show tighter mid‑range dispersion: Aetna’s IQR is $238.10 and UnitedHealth Group’s IQR is $346.80, indicating more consistency near their medians. Comparing extremes, Blue Cross Blue Shield exhibits the widest interquartile dispersion, suggesting greater variability in contracted commercial rates, while Aetna is the tightest among the payers listed. Published median and mean differences also reflect that Cigna and Blue Cross Blue Shield push higher upper quartiles, whereas Aetna and UnitedHealth Group cluster more closely around middle values.